cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Editas Medicine Inc
83 own
53 watching
Current Price
$11.12
$-0.14
(-1.24%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
764.63M
52-Week High
52-Week High
21.595
52-Week Low
52-Week Low
7.705
Average Volume
Average Volume
1.63M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization764.63M
icon52-Week High21.595
icon52-Week Low7.705
iconAverage Volume1.63M
iconDividend Yield--
iconP/E Ratio--
What does the Editas Medicine Inc do?
Developing gene editing therapies based on CRISPR/Cas9 technology.
Read More
How much money does Editas Medicine Inc make?
News & Events about Editas Medicine Inc.
Globe Newswire
19days ago
Shoreline to obtain an exclusive license to SLEEK knock-in technology for iPSC-derived NK cells, an exclusive license to SLEEK for iPSC-derived macrophages in oncology anda non-exclusive license for AsCas12a Shoreline to acquire Editas Medicines iNK cell franchise, including EDIT-202 and certain ...
Globe Newswire
29days ago
Strategic reprioritization of portfolio to focus on hemoglobinopathies and in vivo gene editing Discontinuing internal investments in inherited retinal diseases and in preclinical wholly owned iNK programs Mark S. Shearman, Ph.D., Chief Scientific Officer to step down, departing March 31 ...
Zolmax
1month ago
ProKidney (NASDAQ:PROK Get Rating) and Editas Medicine (NASDAQ:EDIT Get Rating) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their profitability, institutional ownership, dividends, risk, earnings, ...
Ticker Report
1month ago
Editas Medicine, Inc. (NASDAQ:EDIT Get Rating) has been assigned an average recommendation of Hold from the thirteen brokerages that are covering the firm, MarketBeat.com reports. Three investment analysts have rated the stock with a sell rating, six have issued a hold rating ...
Benzinga
3 months ago
Over the past 3 months, 5 analysts have published their opinion on Editas Medicine (NASDAQ:EDIT) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year. Latest Ratings for ...
Frequently Asked Questions
Frequently Asked Questions
What is Editas Medicine Inc share price today?
plus_minus_icon
Can Indians buy Editas Medicine Inc shares?
plus_minus_icon
How can I buy Editas Medicine Inc shares from India?
plus_minus_icon
Can Fractional shares of Editas Medicine Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Editas Medicine Inc stocks?
plus_minus_icon
What is today’s traded volume of Editas Medicine Inc?
plus_minus_icon
What is today’s market capitalisation of Editas Medicine Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Editas Medicine Inc?
plus_minus_icon
What percentage is Editas Medicine Inc down from its 52-Week High?
plus_minus_icon
What percentage is Editas Medicine Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$11.12
$-0.14
(-1.24%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00